With over 25 years of research, development and commercial experience in neuroscience, we are fully committed to improving health outcomes for patients suffering from debilitating neurological disorders.

Our Commitment to Neuroscience

Neuroscience is advancing at an unprecedented rate and we are proud to be at the forefront of this transformation. Our focus is on enabling children and adults suffering from debilitating and degenerative neurological disorders to take back control of their lives, and our long‐term commitment to advancing neuroscience and toxins research is evidenced by over 25 years of clinical experience.

Neuroscience is central to Ipsen’s internal innovation and external partnering, integral to the company’s overall strategy, and a key driver of long‐term value and growth.

Our Areas of Expertise

Our Neuroscience Pipeline

As the only company with recombinant botulinum neurotoxins in our portfolio and in active clinical development, our R&D centers around the world are pioneering research in neuroscience. Recombinant toxins, with longer duration of action in preclinical models, could potentially give healthcare providers the ability to choose the most appropriate neurotoxin for their patients. Recognizing the need for new, longer-lasting treatment options, Ipsen has leveraged its knowledge and more than 25 years’ experience of native botulinum neurotoxins and R&D capabilities to harness the power and potential of toxin biology and to pioneer innovation in toxin therapy.

In addition to our expertise in neurotoxins, our strategy includes research into rare neurodegenerative disorders such as Huntington’s disease, rare neuroinflammatory disorders, movement disorders such as Parkinson’s disease, and rare neurodevelopmental disorders such as Angelman syndrome. Our strong development capabilities cover all stages of the drug development process, and we have a successful track record of global regulatory approvals and accelerated pathways, making Ipsen an ideal partner for neuroscience innovation.

Learn more about our pipeline
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023